UNSPSC 51411703: Ciclosidomine

This classification denotes a vasodilating agent and nitric oxide-releasing compound, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S7P608OW2O. European Medicines Agency schedules Ciclosidomine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06249MIG. Ciclosidomine generally arises in the molecular formula C13H20N4O3.

UNSPSC 51411703 Ciclosidomine, a Commodity code, encompasses emergency and specialty medications that state and local governments procure for emergency response, public health, and pharmacy benefit programs. State and local buyers under this code include municipal fire rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. The scope of procurement spans individual branded and generic pharmaceutical products supplied through established distribution channels, with vendors required to meet strict expiration-date requirements, FDA compliance, cGMP certification, and DSCSA supply-chain security standards. Issuing bodies typically enforce product-liability warranties, require Safety Data Sheets compliant with OSHA Hazard Communication Standards, and impose performance penalties for late reporting or delivery failures.

Recent activity shows geographic spread across Florida, Texas, and the Upper Midwest. The City of Tampa's Purchasing Department posted an IFB (Solicitation 26P00188) on April 24, 2026, soliciting sealed bids for Advanced Life Support Medications—including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials—for Tampa Fire Rescue with a response deadline of April 8, 2026 and estimated contract value of $40,000, featuring a 5 percent SLBE bid discount. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in early April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, signaling exploratory procurement strategy before formal solicitation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP (S1070000015802) in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to work through three authorized wholesalers and offering contract awards effective July 1, 2026.